In a bid to tap overseas market, Glenmark Pharmaceuticals Ltd's wholly owned US subsidiary has entered into a product development and marketing licence agreement with US-based K V Pharmaceutical Company
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
In a bid to tap the potential in Latin America, Glenmark Pharmaceuticals Ltd has acquired Brazil-based Laboratorios Klinger, ranked among the top 50 in that country, for $5.2 million.\n\n\n\n
A sharp increase in interest costs has caused Glenmark Pharmaceuticals to post a consolidated net profit of Rs 80.9 crore for the second quarter, 31 percent lower than the Rs 117.3 crore for the previous corresponding quarter.
Glenmark Pharmaceuticals Ltd has set up a wholly-owned subsidiary in the US to step up presence for the company's formulations and Active Pharmaceuticals Ingredients in that market.
Glenmark Pharmaceuticals Ltd plans to divest its subsidiary Glenmark Laboratories Ltd to Mark Saldanha and his associates for Rs 350 million. It also plans to sell its manufacturing plant at Verna, Goa.
The rally in the equity markets in the second half of 2023 has led to a sharp surge in the cutoff for stocks to qualify as largecaps and midcaps. On the latest list put out by the Association of Mutual Funds in India (Amfi), the smallest largecap stock now has a market capitalisation (m-cap) of Rs 67,000 crore, 35 per cent higher than in July 2023. In the case of midcaps, the cutoff has surged 26 per cent to Rs 22,000 crore.
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis.
Overseas direct investment by Indian companies fell by over 53 per cent year-on-year to $1.16 billion in July 2014, as per RBI data.
Glenmark Generics Inc has settled the litigation pending between the company and GSK over patent actions concerning atovaquone and proguanil hydrochloride 250mg/100mg tablets, the generic version of GSK's Malarone tablets, Glenmark Pharma said.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy's Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
R&D is increasingly becoming an area of focus for Indian pharma companies and most of the big companies are spending about 6%-7% of their revenues on R&D activity.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The FMCG index gained more than 1% on the back of stellar gains in ITC.
Russia's central bank early on Tuesday raised interest rates to 17 per cent to counter the 50 per cent rouble fall in six months.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
Top 5 losers include Lupin, Cipla, Sun Pharma, Dr Reddy's Lab and GAIL down 1.6%-11%.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Sun Pharma was by far the biggest gainer in the Sensex pack, surging 8.13 per cent, followed by Dr Reddy's at 4.92 per cent.
FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
Markets finished lower for the sixth consecutive day as hopes of the Goods and Services tax (GST) bill being passed in the current session of the Parliament faded considerably.
All the sectoral indices, led by realty, metal, consumer durables and power were trading in the negative zone on Thursday.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
The upcoming July derivatives expiry later in the week would also add some volatility to the market proceedings.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Bank shares were the top gainer in early trades with Bank of Baroda up over 4%.
The Sensex ended at at 27,676, lower by 210 points and the Nifty broke the psychological level of 8,400 to end at 83877 down 70 points.
The Nifty had hit its third successive record high of 7,922.70 today.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances